Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30

$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –

Vaxart EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Vaxart's EV/EBITDA was 1.1× on Oct 19, 2026.

Period	Period end	Value	Change (pts)
2026	Oct 19, 2026	1.1×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VXRT.

Revenue growth22.3% · median 151.2%

Operating margin16.6% · median -69.8%

Net margin16.0% · median -39.8%

Advertisement
300 × 250

See a number that looks wrong?